Advanced Biomedical Research (ABR) says that LabPas CT is live in its production environment and will be used to automate the conduct of its phase I trials in its 72-bed research unit
"ABR is committed to employing the latest information technology to perform, manage and monitor clinical trials in a cost-efficient and rapid manner," said Michael Willett, president and CEO of ABR.
"The adoption of LabPas CT has gone remarkably smoothly thanks to the combination of outstanding support from the LabPas staff and the efforts and incredible enthusiasm of our own clinical staff".
John Rosenblum, president and CEO of Green Mountain Logic, developer of LabPas CT, noted, "ABR's sophisticated and innovative approach to the conduct of clinical trials positions them at the leading edge of phase I clinical trials".
ABR is a full-service, phase I-IV global CRO dedicated to meeting the needs of pharmaceutical, biotechnology, and medical device companies.
ABR offers an extensive range of clinical services including clinical study design, strategic and regulatory consulting, project management, monitoring, clinical data management, biostatistics, pharmacokinetic and pharmacodynamic analysis, quality assurance auditing, medical writing, pharmacovigilance and regulatory submissions.
ABR has tested numerous innovator and generic compounds in its state-of-the-art phase I-II clinical research facilities in New Jersey and performs a wide range of clinical trials including first-in-human, dose escalation, proof of concept, bioavailability, bioequivalence, PK/PD, fed-fasted, drug-drug and drug-alcohol interactions and thorough or definitive QTc evaluations.
ABR has also recently expanded its portfolio of services to include bioanalytical, formulation development, organic synthesis and clinical supplies release and stability testing through it's partner, Frontage Laboratories.
